Biovel Life Sciences (P) Ltd is planning to introduce a range of vaccines and therapeutic proteins in the domestic market by mid 2008. These are Polysaccharide vaccines for Typhoid and Hib (Haemophilias Influenza-B) vaccine, a remedy for fatal brain infection in babies.
The Indian market size for typhoid vaccines is Rs 25 crore with GSK being a major player among others and the HiB market is valued at Rs 100 crore. Biovel Life Sciences (P) Ltd has an established procedure to conjugate PRP with the protein to convert B-cell dependent vaccine to T-cell dependent vaccine. This method increases the safety and applicability of vaccine. Biovel is also working towards conjugating Vi-polysaccharide with a protein to increase its applicability.
The Sodium Enoxaparin (Thrombovel) introduced in four different strengths has been well accepted in market and made its entry into some of the leading hospitals in India. With regards to global market entry, Thrombovel is in the process of registration in the non-regulated countries. Biovel has tied-up with a leading Indian company (name withheld) to co-market the brand in selective international markets.
On the technology transfer of Pfenex Expression to manufacture Human Growth Hormone (HGH), Biovel is in the process of importing the clone. Permissions from regulatory authorities have been sought to conduct the experiments at its facility. The production unit infrastructure consists of two cGMP pilot plants for in-house or contract works. The total clean room area spans over 40,000 sq. ft. There are two independent vial fill finish lines, one of which is attached to the lyophilizer besides an advanced PFS system. The facility can simultaneously produce three independent biologicals using 20 litre, 100 litre and 300 litre fermenters followed by downstream processing and purification systems. In addition, there is also a state-of-the-art water purification system which can support the needs of the production unit.